Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
2017_Summer_CMTA_Report
Fall_2020_CMTA_Report
CMTA_2016_Annual_Report
The Fall 2021 CMTA Report
…out walking, riding and swimming to raise money for CMTA-STAR research—everything from the Bucks County annual picnic to the daylong extravaganzas mounted by the Vermont Cycle (and Walk!) 4 CMT…
Type 2 Update: One Patient’s Diagnostic Odyssey with SORD
…scholar from University College of London— discovered the SORD mutation “hidden” from the gene analysis software that most researchers use. Using a different strategy, the researchers found the relevant variations…
CMTA Volunteer Spotlight
…that the best way to live with CMT is by working to raise awareness, help fund research and create community with other CMTers. My most treasured volunteer role is with…
New Gene Therapy Development Program for CMT2A
…that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP). The license…
CMTA Announces Addition of Health Insurance Industry Veteran Wendy Arnone to the Board of Directors
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of health…
Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
…Neuropathy Clinics and Cutaneous Innervation Laboratory in the Department of Neurology at the University of Rochester, and a member of the STAR (Strategy to Accelerate Research) advisory board for the…
CMTA Spring 2024 Report: Progress and Impact that Empowers Communities
…webinars, local meetings, and a Patient and Research Summit. Sue expresses gratitude to the community for their courage, resilience, and commitment. The CMTA’s community-led outreach efforts in 2023 included successful…